CN108671094B - A pharmaceutical composition for treating gout and preparation method thereof - Google Patents
A pharmaceutical composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN108671094B CN108671094B CN201810746258.4A CN201810746258A CN108671094B CN 108671094 B CN108671094 B CN 108671094B CN 201810746258 A CN201810746258 A CN 201810746258A CN 108671094 B CN108671094 B CN 108671094B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- radix
- treating gout
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000218176 Corydalis Species 0.000 claims abstract description 22
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 244000227573 Desmodium styracifolium Species 0.000 claims abstract description 17
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 17
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 17
- 241000241550 Cyathula Species 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 15
- 235000011477 liquorice Nutrition 0.000 claims abstract description 15
- 241000255789 Bombyx mori Species 0.000 claims abstract description 13
- 241000282817 Bovidae Species 0.000 claims abstract description 13
- 241001254604 Angelica pubescens Species 0.000 claims abstract description 12
- 241001071795 Gentiana Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 240000001398 Typha domingensis Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 238000002156 mixing Methods 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 241000255791 Bombyx Species 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 17
- 208000002193 Pain Diseases 0.000 abstract description 16
- 230000036407 pain Effects 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 11
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 17
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 14
- 229940116269 uric acid Drugs 0.000 description 14
- 241000233948 Typha Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 208000006820 Arthralgia Diseases 0.000 description 11
- 241000501743 Gentiana macrophylla Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229950000193 oteracil Drugs 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000220485 Fabaceae Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000501719 Gentiana straminea Species 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 244000097863 Grifola umbellata Species 0.000 description 1
- 235000002897 Grifola umbellata Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241001518821 Typha orientalis Species 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating gout and a preparation method thereof, wherein the pharmaceutical composition is prepared from salvia miltiorrhiza, medicinal cyathula root, pubescent angelica root, large-leaved gentian, corydalis tuber, stiff silkworm, cortex albiziae, desmodium styracifolium, cattail pollen, antelope horn, laojunci and liquorice. Aiming at the pathogenesis of gout, the pharmaceutical composition mainly promotes blood circulation, dispels wind, and gives consideration to the methods of nourishing liver and kidney and relieving pain, so that the gout can be treated by treating both symptoms and root causes.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a pharmaceutical composition for treating gout and a preparation method thereof.
Background
Gout (Gout), which is a disease caused by purine metabolism disorder and/or reduced uric acid excretion due to various reasons, is characterized in that sodium urate crystals are formed in joints and other tissues, which can cause repeated attack of acute arthritis, the sodium urate crystals can further form lumps to form tophus, which causes chronic arthritis, joint deformity, even can cause loss of joint function, and the urate can also be produced in kidneys to cause gouty nephropathy. Gout occurs well in men 40-50 years old and postmenopausal women, but the age of onset is gradually advancing toward a lower age. According to epidemiological research, the number of patients suffering from hyperuricemia currently exceeds 1 hundred million in China, and nearly 2000 million patients with gout are diagnosed, and the pain of the patients is increased at a speed of about 10% per year, so that the patients suffering from gout attack become one of the diseases which seriously affect the life and work of people.
At present, the western medicine generally treats gout from the symptoms, and applies anti-inflammatory analgesic drugs, uric acid formation inhibition drugs or uric acid excretion promotion drugs and the like, can only relieve the clinical symptoms of gout to a certain extent, can treat symptoms but not root causes, and needs to take medicines for a long time in order to relieve the symptoms, and the gout rapidly recurs after stopping taking the medicines, so that the treatment effect is limited, and the western medicine can bring serious side effects of the medicines, such as nausea, vomiting, dyspepsia, headache, dizziness and the like to patients.
The traditional Chinese medicine considers that gout belongs to the category of arthralgia in the traditional Chinese medicine, and a chapter in Su Wen Bi Lun indicates that the so-called arthralgia is caused by severe wind, cold and dampness, and the external causes of the arthralgia are wind, cold and dampness which are mixed and become the arthralgia. The victory of wind-qi is arthralgia-syndrome, the victory of cold-qi is arthralgia-syndrome, and the victory of damp-qi is arthralgia-syndrome. The disease name of gout is firstly proposed by Zhu Danxi in the book of Greek treatise, "gout is usually painful, the pain part is red, swollen and scorching or the body is full of heat", and the gout treatment principle of "using pungent-heat agent to disperse cold-dampness, develop the striae and make blood flow through" is proposed. The pathogenesis of gout is supplemented and enriched by the traditional Chinese medical doctors in the later world, and is considered to comprise: deficiency of vital qi at the early stage of gout disease, such as deficiency of innate essence, deficiency of liver and kidney, disharmony between nutrient and defensive qi, deficiency of qi and blood, and obstruction of phlegm-dampness, which results in invasion of exogenous pathogenic factors, obstruction of channels and collaterals, unsmooth circulation of qi and blood, and increase of obstruction of wind-cold-dampness. Liver pertains to wood, kidney pertains to water, and both of them nourish one another and are damaged by one injury. If liver and kidney are deficient, essence and blood are deficient, muscles and bones are not nourished, and liver and kidney qi is weakened, it is easy to catch wind-cold-dampness pathogen. Defensive qi is mainly the functional basis-defensive qi and defense in the category of traditional Chinese medicine, while nutritive blood is mainly the material basis, and both can influence each other and restrain each other; when viewed from the disease position, defensive qi is on the exterior, nutritive blood is in the interior, qi is the commander of blood, blood is the mother of qi, qi is vigorous when blood is vigorous, blood is vigorous when qi is vigorous, blood is circulated when qi circulates, blood stasis is caused by qi stagnation, nutrient-defense imbalance is susceptible to exogenous pathogenic factors, exogenous pathogenic factors invade, and unsmooth circulation of qi and blood and malnutrition of tendons and vessels are easy to cause. Aiming at the treatment of gout, gout powder, gout decoction, Simiao pills, modified Simiao powder, modified Sanmiao pills and the like appear in sequence, and a certain treatment effect is achieved, but not ideal.
The inventor provides a pharmaceutical composition for treating gout with better effect and a preparation method thereof on the basis of comprehensively researching the pathogenesis and treatment rule of the existing gout.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating gout, which is characterized by being prepared from salvia miltiorrhiza, medicinal cyathula root, radix angelicae pubescentis, gentiana macrophylla, corydalis tuber, stiff silkworm, cortex albiziae, desmodium styracifolium, cattail pollen, antelope horn, laojunci and liquorice.
Preferably, the pharmaceutical composition is prepared from 10-15 parts of salvia miltiorrhiza, 10-15 parts of medicinal cyathula root, 10-15 parts of pubescent angelica root, 5-10 parts of gentiana macrophylla, 5-10 parts of corydalis tuber, 5-10 parts of stiff silkworm, 3-5 parts of cortex albiziae, 3-5 parts of desmodium styracifolium, 3-5 parts of cattail pollen, 1-2 parts of antelope horn, 1-2 parts of monarch hair and 1-2 parts of liquorice.
Preferably, the pharmaceutical composition is prepared from 12-14 parts of salvia miltiorrhiza, 12-14 parts of medicinal cyathula root, 12-14 parts of pubescent angelica root, 6-8 parts of gentiana macrophylla, 6-8 parts of corydalis tuber, 6-8 parts of stiff silkworm, 2-4 parts of cortex albiziae, 2-4 parts of desmodium styracifolium, 2-4 parts of cattail pollen, 1-2 parts of antelope horn, 1-2 parts of monarch hair and 1-2 parts of liquorice.
Preferably, the pharmaceutical composition is prepared from 13 parts of salvia miltiorrhiza, 13 parts of medicinal cyathula root, 13 parts of pubescent angelica root, 13 parts of gentiana macrophylla, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunci and 2 parts of liquorice.
The pharmaceutical composition is added with pharmaceutically acceptable auxiliary materials to prepare an oral pharmaceutical composition, and the dosage form of the oral pharmaceutical composition is selected from: decoction, granules, pills, powder, tablets, capsules and the like, and preferably, the dosage form of the oral pharmaceutical composition is selected from decoction, tablets or capsules.
Preferably, the pharmaceutically acceptable excipients are selected from: diluents, binders, disintegrants, lubricants or glidants, flavoring agents, coating agents, gelatin capsule shells and combinations thereof.
More preferably, the diluent is selected from starch, dextrin, microcrystalline cellulose, and the like; the adhesive is selected from: starch slurry, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, povidone, and the like; the disintegrant is selected from sodium carboxymethyl starch, crospovidone, croscarmellose sodium and the like; the lubricant or glidant is selected from: magnesium stearate, talcum powder, silica gel micropowder and the like.
Still another object of the present invention is to provide a method for preparing a pharmaceutical composition for treating gout, which comprises the steps of:
(1) preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 30-60 mesh sieve, and mixing to obtain powder;
(3) extraction: pulverizing Saviae Miltiorrhizae radix, radix Cyathulae, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, rhizoma corydalis, cortex Albizziae, herba Desmodii Styracifolii, radix Lagocarpae and Glycyrrhrizae radix, sieving with 10-20 mesh sieve, mixing, adding 2-4 times of 50-80% ethanol, reflux-extracting for 1-3 times for 1-2 hr each time, filtering the extractive solution, mixing filtrates, recovering ethanol, optionally concentrating under reduced pressure to obtain extract with relative density of 1.02-1.05 at 25 deg.C;
(4) preparation: and (3) mixing the powder obtained in the step (2) with the filtrate or extract obtained in the step (3) after ethanol is recovered, and adding pharmaceutically acceptable auxiliary materials to prepare the medicinal composition for treating gout.
Preferably, in the step (2), the mixture is sieved by a 40-mesh sieve; sieving with a 20-mesh sieve, mixing, adding 3 times of 70% ethanol, reflux-extracting for 2 times (each time for 1.5 hr), filtering the extractive solutions, mixing filtrates, recovering ethanol, and optionally concentrating under reduced pressure to obtain extract with relative density of 1.02-1.05 at 25 deg.C.
The medicinal composition has the following effects of raw materials:
salvia miltiorrhiza, bitter in taste and slightly cold in nature, belongs to heart and liver channels, is a dry root and rhizome of Salvia miltiorrhiza of Labiatae, has the effects of activating blood circulation to dissipate blood stasis, stimulating the menstrual flow to relieve pain, clearing away the heart-fire to relieve restlessness, cooling blood and resolving carbuncle, and is commonly used for treating chest stuffiness and pains, pyretic stuffiness and pains, restlessness and insomnia, irregular menstruation, dysmenorrheal and amenorrhea, sore and carbuncle and gall.
Cyathula root, sweet in taste, slightly bitter in taste, neutral in nature, and entering liver and kidney meridians, is the dry root of Cyathula root, a plant of Amaranthaceae, has the effects of removing blood stasis, dredging meridians, easing joint movement, inducing diuresis for treating stranguria, and is commonly used for treating amenorrhea, abdominal mass, traumatic injury, foot atrophy and spasm, hematuria, bloody stranguria and other symptoms.
Radix angelicae pubescentis, pungent and bitter in taste and slightly warm in nature, enters kidney and bladder channels, is a dry root of Angelica gigas nakai of Umbelliferae, has the effects of dispelling wind and removing dampness, and relieving arthralgia and pain, and is commonly used for treating anemofrigid-damp arthralgia, waist and knee pain and the like.
Gentiana macrophylla, pungent and bitter in flavor and neutral in nature, which enters stomach, liver and gallbladder meridians, is the dry root of Gentiana macrophylla, Gentiana straminea Maxim and Gentiana macrophylla pall of Gentianaceae, has the effects of dispelling wind-damp, relieving arthralgia and relieving deficiency-heat, and is commonly used for treating muscular spasm, joint soreness and other symptoms.
Corydalis tuber, pungent and bitter in flavor and warm in nature, belongs to liver and spleen channels, is a dry tuber of corydalis tuber of Papaveraceae, has effects of promoting blood circulation, activating qi-flowing and relieving pain, and is commonly used for treating chest, hypochondrium, epigastric pain, thoracic obstruction, dysmenorrhea, postpartum stasis, and swelling and pain due to traumatic injury.
Bombyx Batryticatus, salty and pungent in flavor, neutral in nature, enters liver, lung and stomach channels, is a dry larva dead due to infection of Bombyx Batryticatus of Bombycidae, has effects of calming endogenous wind and relieving spasm, dispelling pathogenic wind and relieving pain, eliminating phlegm and resolving masses, and can be used for treating convulsion and convulsion, tetanus, wind-heat headache, conjunctival congestion and pharyngalgia, rubella and pruritus.
Cortex Albizziae, sweet in taste and neutral in nature, enters heart and liver meridians, is dried bark of Albizziae of Leguminosae, has effects of resolving stagnation, regulating blood, calming heart, and eliminating carbuncle and swelling, and is used for treating uneasiness, melancholy, insomnia, carbuncle and swelling, traumatic injury, etc.
Desmodium styracifolium, sweet and light in flavor, cool in nature, belonging to the liver, kidney and bladder channels, is the dry aerial part of Desmodium styracifolium of Leguminosae, has the effects of removing dampness and jaundice, and inducing diuresis for treating stranguria, and is commonly used for treating jaundice and dark urine, heat stranguria, urolithiasis, painful urination, edema and oliguria, and other symptoms.
Cattail pollen, sweet in taste and neutral in nature, which belongs to liver and pericardium channel, is dry pollen of typha, typha orientalis or congeneric plants in typhaceae, has the effects of stopping bleeding, treating stranguria and removing blood stasis, and is commonly used for treating symptoms such as hematemesis, hemoptysis, metrorrhagia, trauma, amenorrhea, thoracico-abdominal pain, traumatic injury, stranguria with blood and pain, and the like.
Cornu Saigae Tataricae, salty in taste and cold in nature, enters liver and heart meridians, is the horn of male bovine Saigae Tataricae, has effects of suppressing hyperactive liver, calming endogenous wind, clearing liver-fire, improving eyesight, dispelling blood stasis and removing toxic substance, and is used for treating liver wind stirring, convulsion, hyperpyrexia spasm, epilepsy, headache, vertigo, carbuncle, sore and other diseases.
The long-noded gentleman's beard, bitter and slightly pungent in taste, neutral in nature, entering lung meridian, is root or aerial part of Zhuling Xiao, a plant of Asclepiadaceae, has the efficacy of clearing heat and cooling blood, benefiting gallbladder and detoxifying, and is commonly used for treating fever due to yin deficiency, consumptive disease and chronic cough, hemoptysis, hypochondrium distending pain, vomiting, postpartum dysphoria, innominate swelling and pain and other symptoms.
The licorice root, which is the dry root and rhizome of licorice root, swollen licorice root or glabrous licorice root of Leguminosae, has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic material, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the drugs, and is commonly used for treating weakness of spleen and stomach, lassitude and hypodynamia, palpitation and shortness of breath, cough and excessive phlegm, carbuncle and sore pain, and relieving the toxicity and the intensity of the drugs.
The invention has the beneficial effects
1. Aiming at the pathogenesis of gout, the pharmaceutical composition mainly promotes blood circulation, dispels wind, and gives consideration to the methods of nourishing liver and kidney and relieving pain, so that the gout can be treated by treating both symptoms and root causes.
2. The medicinal composition has simple formula, reasonable compatibility of the raw material medicaments, and better gout treatment effect than the existing gout treatment medicaments.
3. The pharmaceutical composition is safe and has no toxic or side effect.
4. The preparation method of the pharmaceutical composition is simple and is suitable for industrial production.
Detailed Description
The present invention is described in more detail below to facilitate an understanding of the present invention.
Embodiment 1 decoction for treating gout
13 parts of salvia miltiorrhiza, 13 parts of medicinal cyathula root, 13 parts of pubescent angelica root, 13 parts of large-leaved gentian, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunxus and 2 parts of liquorice.
The preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 40 mesh sieve, and mixing to obtain powder;
(3) extraction: pulverizing Saviae Miltiorrhizae radix, radix Cyathulae, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, rhizoma corydalis, cortex Albizziae, herba Desmodii Styracifolii, radix Lespedezae Cuneatae and Glycyrrhrizae radix, sieving with 20 mesh sieve, mixing, adding 3 times of 70% ethanol, reflux-extracting for 2 times, each for 1.5 hr, filtering the extractive solutions, mixing the filtrates, and recovering ethanol;
(4) preparation: and (3) mixing the powder obtained in the step (2) with the filtrate obtained in the step (3) after ethanol is recovered to obtain the medicinal composition for treating gout.
Example 2: tablet for treating gout
10 parts of salvia miltiorrhiza, 10 parts of medicinal cyathula root, 10 parts of pubescent angelica root, 5 parts of large-leaved gentian, 5 parts of corydalis tuber, 5 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunxus and 1 part of liquorice.
(1) Preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 60 mesh sieve, and mixing to obtain powder;
(3) extraction: pulverizing Saviae Miltiorrhizae radix, radix Cyathulae, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, rhizoma corydalis, cortex Albizziae, herba Desmodii Styracifolii, radix Lespedezae Cuneatae and Glycyrrhrizae radix, sieving with 20 mesh sieve, mixing, adding 2 times of 80% ethanol, reflux-extracting for 2 times, each for 1 hr, filtering the extractive solutions, mixing the filtrates, recovering ethanol, and optionally concentrating under reduced pressure to obtain extract with relative density of 1.02-1.05 at 25 deg.C;
(4) preparation: and (3) mixing the powder obtained in the step (2) with the filtrate or extract obtained in the step (3) after ethanol recovery, adding a diluent, an adhesive, a disintegrating agent and a lubricant, performing wet granulation, and tabletting to obtain the pharmaceutical composition for treating gout.
Example 3, a capsule for the treatment of gout.
15 parts of salvia miltiorrhiza, 15 parts of medicinal cyathula root, 15 parts of pubescent angelica root, 10 parts of large-leaved gentian, 10 parts of corydalis tuber, 10 parts of stiff silkworm, 5 parts of cortex albiziae, 5 parts of desmodium styracifolium, 5 parts of cattail pollen, 2 parts of antelope horn, 2 parts of laojunxus and 2 parts of liquorice.
(1) Preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 30 mesh sieve, and mixing to obtain powder;
(3) extraction: pulverizing Saviae Miltiorrhizae radix, radix Cyathulae, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, rhizoma corydalis, cortex Albizziae, herba Desmodii Styracifolii, radix Lespedezae Cuneatae and Glycyrrhrizae radix, sieving with 10 mesh sieve, mixing, adding 4 times of 50% ethanol, reflux-extracting for 2 times, each for 2 hr, filtering the extractive solutions, mixing the filtrates, recovering ethanol, optionally concentrating under reduced pressure to obtain extract with relative density of 1.02-1.05 at 25 deg.C;
(4) preparation: and (3) mixing the powder obtained in the step (2) with the filtrate or extract obtained in the step (3) after ethanol is recovered, adding a diluent, an adhesive, a disintegrating agent and a lubricant, performing wet granulation, and filling the mixture into a gelatin capsule shell to obtain the capsule for treating gout.
Effect example 1: the influence of the pharmaceutical composition on the hyperuricemia of mice caused by potassium oxonate
1.1 Experimental drugs
The traditional Chinese medicine extract 1: 13 parts of salvia miltiorrhiza, 13 parts of medicinal cyathula root, 13 parts of pubescent angelica root, 13 parts of large-leaved gentian, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunxus and 2 parts of liquorice;
the traditional Chinese medicine extract 2: 15 parts of salvia miltiorrhiza, 15 parts of medicinal cyathula root, 15 parts of pubescent angelica root, 10 parts of large-leaved gentian, 10 parts of corydalis tuber, 10 parts of stiff silkworm, 5 parts of cortex albiziae, 5 parts of desmodium styracifolium, 5 parts of cattail pollen, 2 parts of antelope horn, 2 parts of laojunxus and 2 parts of liquorice;
the traditional Chinese medicine extract 3: 10 parts of salvia miltiorrhiza, 10 parts of medicinal cyathula root, 10 parts of pubescent angelica root, 5 parts of large-leaved gentian, 5 parts of corydalis tuber, 5 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunxus and 1 part of liquorice;
positive control drug: allopurinol.
Wherein, the traditional Chinese medicine extract 1-3 is prepared according to the following method:
(1) preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 40 mesh sieve, and mixing to obtain powder;
(3) extraction: crushing the salvia miltiorrhiza, the radix cyathulae, the radix angelicae pubescentis, the gentiana macrophylla, the rhizoma corydalis, the cortex albiziae, the desmodium styracifolium, the radix laevigatae and the liquorice, sieving with a 20-mesh sieve, uniformly mixing, adding 3 times of 70% ethanol, performing reflux extraction for 2 times, performing 1.5 hours each time, filtering an extracting solution, combining filtrates, recovering ethanol, performing reduced pressure concentration to obtain an extract with the relative density of 1.02-1.05 at 25 ℃, adding the powder obtained in the step (2), and mixing to obtain the medicinal composition for treating gout, so as to obtain the traditional Chinese medicine extract.
1.2 establishment of Experimental model
60 male Kunming mice with the weight of 18-22g are randomly divided into a blank group, a model group, 1-3 groups and a positive control group, each group comprises 10 mice, after adaptive feeding is carried out for 1d, the mice are subjected to intragastric administration, wherein the blank group and the model group are subjected to intragastric administration of physiological saline, the intragastric administration volumes of the corresponding drugs of the 1-3 groups and the positive control group are 0.5ml, the administration amount of the 1-3 groups of the mice is 10g crude drug/Kg body weight, and the administration amount of the positive control group is 0.05g/Kg body weight. Administering the medicine 1 time per day for 7 days continuously, after the last administration for 1h, injecting 0.3g/Kg body weight of Potassium Oxonate into abdominal cavity of other mice except for blank group, after 2h, collecting blood from orbital vein of mice, measuring serum uric acid content, and calculating serum uric acid inhibition rate, wherein the specific results are shown in Table 1, wherein
The serum uric acid inhibition rate is (serum uric acid content of model group-serum uric acid content of experimental group)/serum uric acid content of model group x 100%.
1.3 results of the experiment
A multi-factor analysis of variance module of statistical software SPSS is used for data analysis, and P <0.05 indicates that the difference has statistical significance.
TABLE 1 Effect of pharmaceutical compositions on Potassium Oxonate induced hyperuricemia in mice
Comparison with blank group: Δ P < 0.01; comparison with model groups: p <0.05, P < 0.01.
The experimental result in table 1 shows that the serum uric acid content of mice in a model group is obviously increased after potassium oxonate is injected in an abdominal cavity, which indicates that the modeling is successful, the serum uric acid level of the mice is reduced to a certain extent after the traditional Chinese medicine extract 1-3 and allopurinol are administrated by intragastric administration, wherein the serum uric acid inhibition rate of the allopurinol to the hyperuricemia mice caused by potassium oxonate is 17.92%, while the serum uric acid inhibition rate of the traditional Chinese medicine extract 1 to the hyperuricemia mice caused by potassium oxonate is most obvious, and the serum uric acid inhibition rate of the traditional Chinese medicine extract to the hyperuricemia mice caused by potassium oxonate reaches 26.51%, thus proving that the traditional Chinese medicine extract has an excellent effect of inhibiting hyperuricemia.
Effect example 2: the influence of the pharmaceutical composition on the writhing reaction of mice caused by acetic acid
2.1 Experimental drugs
The traditional Chinese medicine extract 1: 13 parts of salvia miltiorrhiza, 13 parts of medicinal cyathula root, 13 parts of pubescent angelica root, 13 parts of gentiana macrophylla, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunxus and 2 parts of liquorice, and the preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 40 mesh sieve, and mixing to obtain powder;
(3) extraction: crushing the salvia miltiorrhiza, the radix cyathulae, the radix angelicae pubescentis, the gentiana macrophylla, the rhizoma corydalis, the cortex albiziae, the desmodium styracifolium, the radix laevigatae and the liquorice, sieving with a 20-mesh sieve, uniformly mixing, adding 3 times of 70% ethanol, performing reflux extraction for 2 times, performing 1.5 hours each time, filtering an extracting solution, combining filtrates, recovering ethanol, performing reduced pressure concentration to obtain an extract with the relative density of 1.02-1.05 at 25 ℃, adding the powder obtained in the step (2), and mixing to obtain the medicinal composition for treating gout, so as to obtain the traditional Chinese medicine extract.
Positive control drug: indomethacin.
A molding agent: 0.6% acetic acid solution.
2.2 establishment of Experimental model
The male Kunming mice are 30 mice with the weight of 18-22g, and are randomly divided into a model group, an invention group and a positive control group, each group is 10 mice, after the mice are adaptively raised for 1d, the mice are subjected to intragastric administration, wherein the model group is subjected to intragastric administration by normal saline, the mice are subjected to intragastric administration by the invention group and the positive control group, the intragastric administration volumes are 0.5ml, the administration amount of the mice is 10g crude drug/Kg weight, and the administration amount of the mice is 0.01g/Kg weight. The administration is carried out 1 time per day for 7 days continuously, each group of mice is subjected to intraperitoneal injection of 0.6% acetic acid solution 0.2 mL/mouse after the last administration for 1 hour, the times of mouse writhing within 20 minutes are recorded, and the inhibition rates of the traditional Chinese medicine extract and the indometacin on the writhing reaction of the mice caused by acetic acid are calculated, wherein the specific results are shown in a table 2
The inhibition rate of mouse writhing response is (number of writhing in model group-number of writhing in experimental group)/number of writhing in model group × 100%.
2.3 results of the experiment
A multi-factor analysis of variance module of statistical software SPSS is used for data analysis, and P <0.05 indicates that the difference has statistical significance.
TABLE 2 Effect of pharmaceutical compositions on acetic acid-induced writhing response in mice
Comparison with model groups: p < 0.01.
The experimental results in table 2 show that the frequency of writhing reaction of mice caused by intraperitoneal injection of acetic acid is obviously reduced after the traditional Chinese medicine extract and indometacin are administered by gavage, and the traditional Chinese medicine extract has an excellent analgesic effect.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (6)
1. A pharmaceutical composition for treating gout is characterized by being prepared from 13 parts of salvia miltiorrhiza, 13 parts of medicinal cyathula root, 13 parts of pubescent angelica root, 13 parts of large-leaved gentian, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope horn, 1 part of laojunci and 2 parts of liquorice.
2. The pharmaceutical composition for treating gout according to claim 1, wherein the pharmaceutical composition is prepared into an oral pharmaceutical composition after adding pharmaceutically acceptable auxiliary materials.
3. The pharmaceutical composition for treating gout according to claim 2, wherein the pharmaceutically acceptable excipients are selected from the group consisting of: diluents, binders, disintegrants, lubricants or glidants, flavoring agents, coating agents, gelatin capsule shells and combinations thereof.
4. The pharmaceutical composition for treating gout according to claim 2, wherein the oral pharmaceutical composition is selected from the group consisting of: decoction, granule, pill, powder, tablet or capsule.
5. The pharmaceutical composition for treating gout according to claim 4, wherein the oral pharmaceutical composition is selected from decoction, tablets or capsules.
6. The method for preparing a pharmaceutical composition for treating gout according to any one of claims 1 to 5, comprising the steps of:
(1) preparing materials: weighing the raw materials according to a formula;
(2) crushing: respectively pulverizing Bombyx Batryticatus, cornu Saigae Tataricae and pollen Typhae, sieving with 40 mesh sieve, and mixing to obtain powder;
(3) extraction: pulverizing Saviae Miltiorrhizae radix, radix Cyathulae, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, rhizoma corydalis, cortex Albizziae, herba Desmodii Styracifolii, radix Lespedezae Cuneatae and Glycyrrhrizae radix, sieving with 20 mesh sieve, mixing, adding 3 times of 70% ethanol, reflux-extracting for 2 times (each time for 1.5 hr), filtering the extractive solutions, mixing the filtrates, recovering ethanol, optionally concentrating under reduced pressure to obtain extract with relative density of 1.02-1.05 at 25 deg.C;
(4) preparation: and (3) mixing the powder obtained in the step (2) with the filtrate or extract obtained in the step (3) after ethanol is recovered, and adding pharmaceutically acceptable auxiliary materials to prepare the pharmaceutical composition for treating gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810746258.4A CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810746258.4A CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108671094A CN108671094A (en) | 2018-10-19 |
| CN108671094B true CN108671094B (en) | 2021-10-01 |
Family
ID=63813539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810746258.4A Active CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108671094B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869670A (en) * | 2010-06-08 | 2010-10-27 | 江苏南星药业有限责任公司 | Anti-gout composition, preparation method and application thereof in preparation of anti-gout drugs |
| CN103893363A (en) * | 2013-10-28 | 2014-07-02 | 东南大学 | Traditional Chinese medicine composition for treating chronic gout and fabrication method thereof |
| CN103933224A (en) * | 2014-04-30 | 2014-07-23 | 周晓明 | Traditional Chinese medicine composition for treating gout |
-
2018
- 2018-07-09 CN CN201810746258.4A patent/CN108671094B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869670A (en) * | 2010-06-08 | 2010-10-27 | 江苏南星药业有限责任公司 | Anti-gout composition, preparation method and application thereof in preparation of anti-gout drugs |
| CN103893363A (en) * | 2013-10-28 | 2014-07-02 | 东南大学 | Traditional Chinese medicine composition for treating chronic gout and fabrication method thereof |
| CN103933224A (en) * | 2014-04-30 | 2014-07-23 | 周晓明 | Traditional Chinese medicine composition for treating gout |
Non-Patent Citations (1)
| Title |
|---|
| "中医药治疗痛风病的研究进展";孙晶，等;《中医药信息》;20160531;第33卷(第5期);第126-129页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108671094A (en) | 2018-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100473404C (en) | Hypertension treating Chinese medicine preparation | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN106421673A (en) | Traditional Chinese medicine composition for treating HPV (human papillomavirus) infection and preparation method thereof | |
| CN106729140B (en) | Compound preparation for treating influenza and preparation method thereof | |
| CN115837058B (en) | Traditional Chinese medicine composition, preparation thereof and application of traditional Chinese medicine composition in preparation of medicines for treating diabetic peripheral neuropathy | |
| CN108671094B (en) | A pharmaceutical composition for treating gout and preparation method thereof | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN103736017A (en) | Traditional Chinese medicine composition for treating intercostal neuralgia and preparation method of traditional Chinese medicine composition | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN102397341A (en) | Traditional Chinese medicine for treating oxyhepatitis | |
| CN112274619B (en) | Composition for relieving dysmenorrhea and application of composition in preparation of medicines, health-care products or foods | |
| CN101112498B (en) | Chinese traditional medicine having functions of promoting blood circulation, relaxing vein and strengthening muscles and bones and method for preparing the same | |
| CN108159150B (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method and application thereof | |
| CN104095940B (en) | A kind of Chinese medicine composition for the treatment of gout | |
| CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN108283668A (en) | A kind of gastric ulcer composition of American-cockroach-extract-containing and preparation method thereof | |
| CN110742983B (en) | Traditional Chinese medicine preparation for treating acute gout attack and preparation method thereof | |
| CN111228403B (en) | Traditional Chinese medicine preparation for preventing and/or treating acute gout attack and preparation method thereof | |
| CN102727575B (en) | Medicine for treating hypertension, hyperlipidemia and hyperglycemia and preparation method of medicine | |
| CN108653460B (en) | Traditional Chinese medicine composition for treating chronic urticaria and preparation method thereof | |
| CN111905053A (en) | Medicine for treating gout and preparation method thereof | |
| CN104398971A (en) | Traditional Chinese medicine composition for treating liver cirrhosis, and preparation method and application thereof | |
| CN113559157A (en) | Traditional Chinese medicine composition for treating chronic hepatitis and application thereof | |
| CN110755519A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231219 Address after: No. 605, Building A, National Intellectual Property and Creative Industry Pilot Park, No. 60 Guoji Road, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee after: Zhengzhou Baoyu Medical Technology Co.,Ltd. Address before: 150040 Heping Road 24, Xiangfang District, Heilongjiang, Harbin Patentee before: HEILONGJIANG University OF CHINESE MEDICINE |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231224 Address after: 1st to 9th floors of the office building on the south side of Red Star Macalline World Expo Home Furnishing Plaza, No.1 Gongnong Road, Qiaokou District, Wuhan City, Hubei Province, 430000 Patentee after: Wuhan Jing'e Tongpu Hospital Co.,Ltd. Address before: No. 605, Building A, National Intellectual Property and Creative Industry Pilot Park, No. 60 Guoji Road, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee before: Zhengzhou Baoyu Medical Technology Co.,Ltd. |